Navigation Links
Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell,,,Line

toxin-Sensitive Cell Line

The transfection efficiency for each plasmid preparation was determined by exposing 7.5 x 106 endotoxin-sensitive RAW 264.7 cells4 to calcium phosphate precipitates containing 15 g of StrataPrep kit, AEC-, MB-, and CsCl-purified pA3-3.4Luc (IL-1Ra promoter/luciferase reporter) plasmid. Luciferase expression in this plasmid is stimulated by endotoxin. Cells were exposed to plasmid-calcium-phosphate precipitates for 5 hours, shocked in glycerol for 90 seconds, and washed. Cells from each plasmid transfection were divided equally into a set of six plates and returned to the incubator.

Forty hours post-transfection, three plates of each plasmid preparation set were treated with an excess (1 g/ml) of E. coli lipopolysaccharide (LPS), while the remaining three plates of each set were not stimulated. After an additional 8 hours of incubation, LPS-stimulated and unstimulated cells for each plasmid preparation were harvested, lysed, and assayed for luciferase activity and total protein. Relative light units (RLU) were normalized to protein concentration and expressed as RLU/mg of protein.

The transfection efficiency of StrataPrep-purified DNA, measured as total RLU/mg of protein for stimulated cells, was 1.3-, 3.4-, and 2340-fold higher than stimulated cells transfected with CsCl, AEC, and MB DNA, respectively (Figure 1). The fold RLU increase over background (RLU LPS-stimulated divided by RLU LPS-unstimulated control) for StrataPrep Kit-, CsCl-, AEC-, and MB-purified plasmid was 29, 18, 12, and 0.16, respectively. The high induction ratio for StrataPrep DNA reflects both a high transfection efficiency (indicated by enhanced LPS stimulation compared with the other preps) and negligible degree of endotoxin contamination, evident from the low LPS-unstimulated bac
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Highest Possible Transformation Efficiencies for High-Throughput Applications
2. New Competent Cells for Highest Transformation Efficiencies
3. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
4. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
5. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
6. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
7. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
8. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
9. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
10. Efficient Transfection of Neurospora Crassa
11. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells
Post Your Comments:
(Date:3/3/2015)... N.J. , March 3, 2015  Regenicin, Inc. ... company specializing in the development of and commercialization of ... tissues and organs, announced today that it has received ... with Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... the Agreement, Amarantus made the final payments due to ...
(Date:3/3/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... Expert Opinion on Biological Therapy , Dr. ... Zhang , at the Henry Ford Hospital in ... 4 (TB4) has the capacity to promote CNS and ... post-injury, leading to neurological recovery in each case.  They ...
(Date:3/3/2015)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a ... pets, announced today that it will release its fourth quarter ... the market close. The Company will host a conference call ... Interested parties may access the call by dialing toll-free (855) ... conference ID 98449349.  The call will also ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Personalized Medicine - ... , The aim of personalized ... right drug to the right patient and, in ... for a patient according to his/her genotype. This ...
Breaking Biology Technology:Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3
... condition of esophagus eliminated in 90 percent ... ... BARRX Medical, Inc., the,global technology leader for treating precancerous conditions of ... a,multi-center U.S. study were free of the highest-risk of Barrett,s,esophagus after ...
... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that ... Annual Global Healthcare Conference on,May 19, 2008 at 4:55 ... 2008 UBS,Global Generic and Specialty Pharmaceuticals Conference on Thursday, ... EDT). The presentations will,be web cast live and may ...
... Escalon Medical Corp.,(Nasdaq: ESMC ) today announced ... March 31, 2008., For the third quarter of ... $6,900,000 reported in the same period last fiscal,year. Product ... the,Company,s business units., Net revenue for the third ...
Cached Biology Technology:New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 2New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 3Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 2Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 2Escalon(R) Reports Third Quarter Fiscal 2008 Results 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 4Escalon(R) Reports Third Quarter Fiscal 2008 Results 5Escalon(R) Reports Third Quarter Fiscal 2008 Results 6Escalon(R) Reports Third Quarter Fiscal 2008 Results 7Escalon(R) Reports Third Quarter Fiscal 2008 Results 8
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... It,s long been known that alcohol use in ... birth defects, but researchers who study fetal alcohol syndrome ... disorder, detecting it early, or effectively treating it, say ... the issue of Developmental Neuroscience , four first-year ...
... How do we begin to understand what early life was ... planet shifted from an oxygen-free and probably ice-covered realm to ... who decodes the early record of life on Earth has ... a significantly clearer picture of this dynamic environment. Alison Olcott ...
... , THE WOODLANDS, Texas , June 15 ... company focused on discovering breakthrough treatments for human disease, announced today ... clinical trial of LX4211 for patients with type 2 ... June 19 – 22, 2010 in San Diego, ...
Cached Biology News:Little is understood about alcohol's effect on fetal development, Georgetown researchers say 2Little is understood about alcohol's effect on fetal development, Georgetown researchers say 3Delineating primary and secondary organic carbon in neoproterozoic glacial sediments 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 3Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 4Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 5
Auto/Zyme Reagent...
4',6-Diamidino-2-phenylindole dihydrochloride...
...
Normal Bovine Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin lev...
Biology Products: